• HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit

  2026-10-14

  A source-limited overview of the HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit, its documented T7 transcription and Cy5-UTP labeling principle, intended measurement contexts, and the boundaries created by the absence of identity-matched research evidence.

• (-)-JQ1 and the Limits of BET Controls

  2026-10-14

  (-)-JQ1 is a JQ1 stereoisomer described by APExBIO as an inactive comparator for BET bromodomain studies. Its conceptual value is to help separate effects linked to the active JQ1 scaffold from effects associated with assay context or unrelated chemistry. A supplied, non-peer-reviewed preprint reports heterogeneous responses to chemical BET inhibition and BRD4 depletion in HPV-16-associated head and neck squamous cell carcinoma, but it does not establish that (-)-JQ1 was used or that its findings translate to this control compound.

• What the GCG–Nucleocapsid Study Shows

  2026-10-13

  Zhao and colleagues reported that SARS-CoV-2 nucleocapsid protein can form RNA-triggered liquid–liquid condensates and that the green-tea polyphenol GCG disrupts this behavior while reducing viral replication in experimental models. The findings support a mechanistic hypothesis, but they do not establish GCG as a COVID-19 treatment or demonstrate that nucleocapsid condensation is the compound’s only relevant target.

• What DCFDA Can—and Cannot—Show in Pancreatic Cancer

  2026-10-13

  The reported DATCPT study presents a pH- and ROS-responsive nanocarrier strategy for orthotopic pancreatic cancer, but the supplied evidence does not establish that 2',7'-dichlorofluorescein diacetate was used or that this probe can specifically verify the proposed chemical cascade. Its value is better understood as a general indicator of intracellular oxidative processes, with important limits on mechanistic interpretation.

• Adaptive Nanocarriers in Pancreatic Cancer: What Is Shown

  2026-10-12

  An evidence-focused overview of the DATCPT study, separating its proposed redox-responsive delivery mechanism and reported preclinical findings from the limitations of broad ROS readouts, model applicability, and the supplied evidence record.

• Tetraethylammonium Chloride: Evidence and Limits

  2026-10-12

  The supplied evidence supports a mechanistic interpretation of ATP-sensitive potassium-channel involvement in insulin release, but it does not directly test tetraethylammonium chloride (TEAC). The principal limitation is therefore one of applicability: findings from imidazoline compounds in isolated mouse islets should not be treated as evidence for TEAC-specific, vascular, clinical, or translational effects.

• Merbromin as a Mixed-Type SARS-CoV-2 Protease Inhibitor

  2026-10-11

  The reference study used high-throughput enzymatic screening to identify merbromin as a selective inhibitor of SARS-CoV-2 3CLpro, also known as Mpro. Kinetic, binding, and docking analyses supported a mixed-type inhibition model, while comparison with other proteases helped define the finding’s selectivity and evidence boundaries.

• Sorafenib in Cancer Biology: Evidence and Limits

  2026-10-10

  A source-grounded overview of Sorafenib (BAY-43-9006) as a multikinase research compound, emphasizing RAF, VEGFR, and PDGFR biology, ATRX-deficient glioma findings, evidence quality, and limits on interpretation.

• From Biotin Signals to Metastatic Mechanisms

  2026-10-09

  A thought-leadership analysis of how fluorescent biotin detection can support mechanistic oncology research, using super-enhancer RNA regulation in nasopharyngeal carcinoma as a case study. The article connects Streptavidin-Cy3 with spatial validation, evidence quality, translational biomarker strategy, and the limits of inferring causality from fluorescence-based assays.

• FK866 (APO866): From NAD Stress to Biomarkers

  2026-10-09

  FK866 (APO866) is best understood not only as a NAMPT inhibitor but as a tool for studying metabolic dependency and treatment-context biomarkers. This evidence-led analysis connects NAD depletion with PARP inhibition, RAS/PI3K alterations, and the limits of translating preclinical findings.

• Dovitinib (TKI-258): Evidence and Research Context

  2026-10-08

  A source-grounded overview of Dovitinib research, including its reported multitarget RTK profile, conceptual applications in oncology, comparison with immune-related epigenetic studies, and key evidence limitations.

• Telatinib (BAY 57-9352): Research Context

  2026-10-08

  Telatinib, also known as BAY 57-9352, is a multikinase research compound associated with VEGFR, c-Kit, and PDGFR signaling. This overview compares supplier-reported target potency with findings from a 2026 in vitro triple-negative breast cancer study, emphasizing interpretation, evidence strength, and limits on translational conclusions.

• Netarsudil in Predictive siRNA Codelivery

  2026-10-07

  Slaughter and colleagues developed a quantitative framework that links ionizable drug structure with siRNA complexation and nanoparticle encapsulation. Netarsudil, also known as AR-13324, emerged as a high-performing candidate and enabled experimental codelivery of CTGF-targeting siRNA in fibrotic human trabecular meshwork cells, although the findings remain preclinical and formulation-focused.

• ROS-Degradable LNPs for Mutant RAS Delivery

  2026-10-07

  Cai and colleagues developed a combinatorial library of thioketal-containing lipid nanoparticles designed to exploit elevated reactive oxygen species in tumor cells. The study identified BAmP-TK-12 as a preferential mRNA delivery vehicle and used it to deliver the RAS-cleaving effector DUF5, producing antitumor effects in cellular and animal models while leaving important questions about selectivity, safety, and clinical translation unresolved.

• Ivermectin, GSDMC and Evidence Boundaries

  2026-10-06

  A source-grounded overview of what a 2024 PDAC study shows about GSDMC biology—and why it does not establish an oncology role for Ivermectin.

7842 records 1/523 page Next 12345 下5页 Last page